Literature DB >> 28189208

Multiparametric evaluation by simultaneous PET-MRI examination in patients with histologically proven laryngeal cancer.

Carlo Cavaliere1, Valeria Romeo2, Marco Aiello1, Massimo Mesolella3, Brigida Iorio3, Luigi Barbuto4, Elena Cantone3, Emanuele Nicolai1, Mario Covello1.   

Abstract

OBJECTIVES: To evaluate the relationship between metabolic 18Fluoro-Deoxyglucose-Positron Emission Tomography (18FDG/PET) and morpho-functional parameters derived by Magnetic Resonance Imaging (MRI) in patients with histologically proven laryngeal cancer. To assess the clinical impact of PET/MRI examination on patient's staging and treatment planning.
METHODS: 16 patients with histologically proven laryngeal cancer were enrolled and underwent whole body PET/CT followed by a dedicated PET/MRI of the head/neck region. Data were separately evaluated by two blinded groups: metabolic (SUV and MTV), diffusion (ADC) and perfusion (Ktrans, Ve, kep and iAUC) maps were obtained by positioning regions of interest (ROIs). Tumoral local extension assessed on PET/MRI was compared to endoscopic findings.
RESULTS: A good inter-observer agreement was found in anatomical location and local extension of PET/MRI lesions (Cohen's kappa 0.9). PET/CT SUV measures highly correlate with ones derived by PET/MRI (e.g., p=0.96 for measures on VOI). Significant correlations among metabolic, diffusion and perfusion parameters have been detected. PET/MRI had a relevant clinical impact, confirming endoscopic findings (6 cases), helping treatment planning (9 cases), and modifying endoscopic primary staging (1 case).
CONCLUSIONS: PET/MRI is useful for primary staging of laryngeal cancer, allowing simultaneous collection of metabolic and functional data and conditioning the therapeutic strategies.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Laryngeal cancer; Magnetic resonance imaging; PET/MRI; Positron emission tomography

Mesh:

Substances:

Year:  2016        PMID: 28189208     DOI: 10.1016/j.ejrad.2016.12.034

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Whole body positron emission tomography-MRI of Erdheim-Chester disease: a case report.

Authors:  Nunzia Garbino; Bruna Punzo; Antonio Todisco; Giovanni Cirillo; Carlo Cavaliere
Journal:  Quant Imaging Med Surg       Date:  2020-12

2.  Simultaneous PET/MRI in assessing the response to chemo/radiotherapy in head and neck carcinoma: initial experience.

Authors:  Valeria Romeo; Brigida Iorio; Massimo Mesolella; Lorenzo Ugga; Francesco Verde; Emanuele Nicolai; Mario Covello
Journal:  Med Oncol       Date:  2018-06-19       Impact factor: 3.064

3.  Clinical utility of simultaneous whole-body 18F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma.

Authors:  Sheng-Chieh Chan; Chih-Hua Yeh; Tzu-Chen Yen; Shu-Hang Ng; Joseph Tung-Chieh Chang; Chien-Yu Lin; Tsang Yen-Ming; Kang-Hsing Fan; Bing-Shen Huang; Cheng-Lung Hsu; Kai-Ping Chang; Hung-Ming Wang; Chun-Ta Liao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-03       Impact factor: 9.236

4.  Novel non-invasive assessment of upper airway inflammation in obstructive sleep apnea using positron emission tomography/magnetic resonance imaging.

Authors:  Oren Cohen; Mira M John; Audrey E Kaufman; Vaishnavi Kundel; Omar Burschtin; Samira Khan; Zahi Fayad; Venkatesh Mani; Neomi A Shah
Journal:  Sleep Breath       Date:  2021-08-26       Impact factor: 2.655

Review 5.  MR Imaging-Histology Correlation by Tailored 3D-Printed Slicer in Oncological Assessment.

Authors:  D Baldi; M Aiello; A Duggento; M Salvatore; C Cavaliere
Journal:  Contrast Media Mol Imaging       Date:  2019-05-29       Impact factor: 3.161

6.  Prognostic value of 18F-FDG PET/MRI in patients with advanced oropharyngeal and hypopharyngeal squamous cell carcinoma.

Authors:  Leonardo Pace; Emanuele Nicolai; Carlo Cavaliere; Luca Basso; Nunzia Garbino; Giacomo Spinato; Marco Salvatore
Journal:  Ann Nucl Med       Date:  2021-02-11       Impact factor: 2.668

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.